Gonca Ozcan, MD
@GoncaOzcanMDHematology-Oncology Fellow @NIH I Alumni @istanbultipf and @UconnIM I Tweets are mine.
Similar User
@ina_lico
@MeghanaSinghMD
@OWBrooks_MD
@FernandoDiazMD1
@KanKParmar
@GroverDheera
@nerealiamd
@JuanChangoMD
@samanthawarrak
Over the past week, we’ve been getting to know our newest #NIHHemeOncFellows, including at a get-together at Director @JenKanakry’s home with our chiefs, associate directors and coordinators, as well as significant others, on hand. #worklifebalance
Our 2nd most downloaded article in 2022: Natural killer cells in antitumour adoptive cell immunotherapy by Katy Rezvani @lab_rezvani & colleagues go.nature.com/3XCAtyh @NatResCancer #NRCtop10of2022
Discussion from @SharonSavageMD from @theNCI on the role of androgens in #telomere biology disorders - hematologic responses seen in most, may lengthen telomeres, studies (including our @nih_nhlbi clinical trial) ongoing! #ASH22 @ASH_hematology @TeamTelomereInc
Our new @NIH_NHLBI fellows are Drs. Nicholas Lee (@NickLeeMD @UTSW_medpeds), Gonca Ozcan (@GoncaOzcanMD @UConnIM), and Kanak Parmar (@KanKParmar @ttuhsc). We welcome all to @NIH!
So excited to share that I will be starting my Hem/Onc fellowship next year at @NIHClinicalCntr !! I feel extremely proud and honored to become a part of such an amazing team! @theNCI @nih_nhlbi @NIH Thanks to all of their support for @UConnIM
Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL. Jabbour, Short, Kantarjian of @MDAndersonNews #Leukemia authors.elsevier.com/a/1g5k18MsWYC4… via @TheLancetHaem #leusm
New meta-analysis: MRD highly prognostic in #AML, regardless of type of response (CR vs. others) or assay sensitivity. More evidence that MRD could be surrogate endpoint in AML | @NicholasShortMD @MDAndersonNews #Leukemia nature.com/articles/s4137… @LeukemiaJnl #leusm
1/5 Our paper @CCR_AACR shows sustained MRD negativity in MM is associated with stool butyrate and healthier plant based diets. @LesokhinMD @MSKCancerCenter @MSKHemOncTrials @AACR @HealthTreeMM @theMMRF @IMFmyeloma @aicrtweets @ASH_hematology #mmsm aacrjournals.org/clincancerres/…
Congratulations to Dr. Rezvani @lab_rezvani for the richly deserved Otis W. And Pearl L. Walters faculty achievement award in clinical research! Congrats to all honorees and awardees for all your efforts conquering cancer! ❤️🤩🎉@MDAndersonNews
Our analysis by @drsangeetmd showing that RUNX1 mutations in AML may not always be adverse, particularly when venetoclax is used. Important data that highlight the need for risk stratification systems that consider not only cyto-molecular features but also type of therapy given.
The prognostic impact of RUNX1 mutations in AML may be treatment-dependent; RUNX1 mutations may not adversely impact outcomes when venetoclax-based regimens are used. onlinelibrary.wiley.com/doi/epdf/10.10…
Check out our manuscript on the CB Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia. Thank you to our mentors @EJShpallMD and @lab_rezvani for their support and guidance in this study. frontiersin.org/articles/10.33…
I am very grateful to have the opportunity to present our work in person at #ASCOQLTY22 in Chicago! Thanks to @OncElias for his mentorship 🙏 Please check out our poster at Poster A session-C2. "Home Based Geriatric Oncology Care: A Feasibility Study" @UConnIM
Very proud of Ye Ethan Li for having his PhD project published in NatMed. His paper shows that trogocytosis drives relapse post CAR NK therapy & that a dual CAR system to modulate NK signaling can improve CAR NK efficacy. Congratulations! @MDAndersonnews rdcu.be/cWBgI
Researchers from our Dr. Katy Rezvani’s lab identified a novel mechanism of relapse following chimeric antigen receptor natural killer cell therapy and developed a strategy to mitigate this process: bit.ly/3dTCTr0 @Lab_Rezvani #CARNK #EndCancer
Kudos to Drs Mailankody and @ESmithMDPhD for this work GPRC5D-Targeted CAR T Cells for Myeloma | NEJM #mmsm @MSKCancerCenter #CARTsm nejm.org/doi/full/10.10…
As a hematologist specializing in #WomensHealth, the impact of Dobbs on patients AND physicians cannot be overstated. @ASH_hematology article featuring @LydiaPecker and other leaders! #WomenInMedicine #MaternalHealth @MaryCushmanMD @DevaSharma1981 ashpublications.org/ashclinicalnew…
Which patients with recurrent #glioblastoma respond to #immunotherapy? Activation of the MAPK/ERK pathway in glioblastoma may induce an inflammatory microenvironment that facilitates response to anti-PD1 treatment. nature.com/articles/s4301…
United States Trends
- 1. Brian Kelly 8.532 posts
- 2. #UFC309 47 B posts
- 3. Mizzou 6.460 posts
- 4. Feds 37,3 B posts
- 5. #MissUniverse 66,4 B posts
- 6. Nebraska 11,7 B posts
- 7. Louisville 6.923 posts
- 8. Gators 11 B posts
- 9. Carson Beck 2.117 posts
- 10. Romero 18 B posts
- 11. Onama 2.279 posts
- 12. #AEWCollision 7.589 posts
- 13. Locke 3.869 posts
- 14. Luther Burden 1.224 posts
- 15. #LAMH 1.041 posts
- 16. Stanford 9.307 posts
- 17. Antifa 32,5 B posts
- 18. #GoDawgs 5.992 posts
- 19. Nuss 3.408 posts
- 20. Arian Smith N/A
Something went wrong.
Something went wrong.